All Oncology News

Sagar S. Patel, MD, discusses data from trials evaluating agents in the Orca platform and where they fit into hematologic malignancy treatment paradigms.

During an Onclive Peer Exchange, panelists examined the utility of ctDNA in bladder cancer and other GU malignancies.

Frontline tislelizumab/chemotherapy yielded sustained PFS outcomes and a meaningful OS improvement vs placebo/chemotherapy in recurrent or metastatic NPC.

Multicancer early detection testing has emerged as an exciting strategy to expand cancer screening.

IMPT generated similar physical QOL scores, local disease control, gastronomy tube dependence, and OS vs IMRT in oropharyngeal squamous cell carcinoma.

Ulrich Steidl, MD, PhD, has been named director of the Montefiore Einstein Comprehensive Cancer Center and vice president of cancer medicine at Montefiore Einstein.

Douglas Flora, MD, LSSBB, discusses how AI is helping oncologists keep up with an evolving field, reinvent care timelines, and connect with patients.

Read below to hear from Drs Markman and Slomovitz on the sessions and abstracts they’re looking forward to at this year’s SGO Annual Meeting on Women’s Cancer.

An NDA for neladalkib in TKI-pretreated, advanced, ALK-positive NSCLC was submitted to the FDA.

Catch up on insights into the global development of breast cancer therapies that are making waves around the world.

Low-cost blood tests that detect multiple blood cancers and diseases have been developed by researchers at UCLA Health.

The final analysis of the phase 1/2 BRUIN trial showed consistent stability or improvements in PROs with pirtobrutinib in CLL/SLL and MCL.

Experts highlight ctDNA-guided strategies, ADCs, and targeted therapies shaping CRC research in the first quarter of 2026.

Jan Philipp Bewersdorf, MD, FACP, detailed findings from a meta-analysis and considerations for the use of luspatercept for anemia in lower-risk MDS.

David R. Wise, MD, PhD, discusses data from a phase 1b study of pasritamig plus docetaxel in mCRPC.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

A new study from researchers at The University of Texas MD Anderson Cancer Center shows that a specialized high-dose type of radiation delivery may improve outcomes in cholangiocarcinoma

GATA2 variants retain enhancer activity, alter differentiation, and may link inflammation to hematologic malignancy risk.

Rana R. McKay, MD, discusses data from the phase 4 OPTYX study of real-world relugolix in prostate cancer.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinib plus venetoclax for chronic lymphocytic leukemia and how it improves QOL.

Cabozantinib was active with no new safety signals in second-line advanced RCC after treatment with frontline checkpoint inhibitor–based therapy.

Research found that adjuvant immunotherapy plus chemotherapy in stage 3 colon cancer was associated with a reduction in recurrence vs chemotherapy alone.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Sagar S. Patel, MD, discusses data from a retrospective analysis of Orca-T and PTCy for hematologic malignancies and its implications for the field.

CTIM-76 received fast track designation from the FDA for pretreated platinum-resistant ovarian cancer.

Neoadjuvant THP demonstrated noninferiority compared with standard TCbHP in patients with stage II or III HER2-positive breast cancer.

Read our recap of top phase 1 and 2 breast cancer data announcements and highlights that may influence further clinical research and developments.

Pembrolizumab plus paclitaxel, with or without bevacizumab, is approved in the EU for pretreated platinum-resistant ovarian cancer with PD-L1 expression.